DPDoctor's PassportEducation
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.
RapidMLAMSRAFoundation

Cancer prevention and modifiable risk

Essential points for quick revision.

Synopsis

Prioritise evidence-based cancer prevention, communicate absolute rather than exaggerated risk, and connect tobacco, alcohol, weight, infection, ultraviolet and occupational interventions to equitable care.

  • Tobacco avoidance and cessation remains the highest-impact modifiable cancer-prevention intervention and reduces cardiovascular and respiratory harm at the same time.
  • Alcohol risk rises with consumption and affects several cancer sites; practical reduction advice should avoid implying that any drinking level is cancer-protective.
  • Maintaining a healthy weight, regular activity and a fibre-rich diet support prevention, but counselling must avoid blame because cancer is multifactorial.

Investigation priorities

01
Structured tobacco assessmentFirst step

Measure current use, dependence, previous quit attempts and readiness.

Management branches

PrioritiseChoose the highest-value change

A routine consultation identifies several potentially modifiable exposures.

  1. Address tobacco first when present, while also identifying alcohol dependence, safeguarding, occupational hazards or symptoms that cannot wait.
  2. Use shared decision-making to select a feasible action and explain the expected broader health benefit without promising cancer prevention.

Key medicines

Varenicline for tobacco dependenceStart 1–2 weeks before the quit date: 0.5 mg orally once daily on days 1–3, 0.5 mg twice daily on days 4–7, then 1 mg twice daily from day 8, usually for 12 weeks; reduce for intolerance and follow the SmPC for severe renal impairment.
Open full textbook Answer 2 questions
Sources and review status7 sources · checked 27 Aug 2026 · clinical review pending
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom